Analysts expect that Stryker Co. (NYSE:SYK) will announce $1.90 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have made estimates for Stryker’s earnings, with estimates ranging from $1.89 to $1.92. Stryker posted earnings per share of $1.69 in the same quarter last year, which would suggest a positive year-over-year growth rate of 12.4%. The business is expected to report its next earnings results on Thursday, October 24th.
According to Zacks, analysts expect that Stryker will report full year earnings of $8.20 per share for the current fiscal year, with EPS estimates ranging from $8.14 to $8.24. For the next year, analysts forecast that the company will post earnings of $9.01 per share, with EPS estimates ranging from $8.91 to $9.07. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow Stryker.
Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, beating the Zacks’ consensus estimate of $1.93 by $0.05. The company had revenue of $3.65 billion during the quarter, compared to the consensus estimate of $3.60 billion. Stryker had a net margin of 24.99% and a return on equity of 25.98%. Stryker’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.76 EPS.
SYK stock traded down $7.05 during mid-day trading on Wednesday, reaching $212.06. The company’s stock had a trading volume of 924,800 shares, compared to its average volume of 1,241,326. The stock has a market cap of $81.66 billion, a PE ratio of 29.01, a PEG ratio of 2.66 and a beta of 0.85. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.26 and a current ratio of 2.07. Stryker has a fifty-two week low of $144.75 and a fifty-two week high of $222.59. The company’s 50 day moving average price is $210.23.
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $2.08 annualized dividend and a dividend yield of 0.98%. Stryker’s dividend payout ratio (DPR) is 28.45%.
In other news, CFO Glenn S. Boehnlein sold 2,700 shares of the stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $214.16, for a total value of $578,232.00. Following the completion of the sale, the chief financial officer now owns 20,633 shares of the company’s stock, valued at approximately $4,418,763.28. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Timothy J. Scannell sold 4,666 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $186.71, for a total transaction of $871,188.86. The disclosure for this sale can be found here. In the last three months, insiders sold 20,097 shares of company stock valued at $4,045,678. Corporate insiders own 7.20% of the company’s stock.
Several institutional investors have recently bought and sold shares of SYK. Founders Capital Management LLC boosted its position in shares of Stryker by 3.9% during the 2nd quarter. Founders Capital Management LLC now owns 10,887 shares of the medical technology company’s stock worth $2,238,000 after purchasing an additional 411 shares during the period. Clarus Wealth Advisors boosted its position in shares of Stryker by 19.3% during the 2nd quarter. Clarus Wealth Advisors now owns 2,111 shares of the medical technology company’s stock worth $434,000 after purchasing an additional 342 shares during the period. Bbva Compass Bancshares Inc. boosted its position in shares of Stryker by 1.1% during the 1st quarter. Bbva Compass Bancshares Inc. now owns 11,663 shares of the medical technology company’s stock worth $2,304,000 after purchasing an additional 123 shares during the period. MainStreet Investment Advisors LLC boosted its position in shares of Stryker by 3.9% during the 1st quarter. MainStreet Investment Advisors LLC now owns 15,532 shares of the medical technology company’s stock worth $3,067,000 after purchasing an additional 589 shares during the period. Finally, Advisory Services Network LLC boosted its position in shares of Stryker by 2.9% during the 1st quarter. Advisory Services Network LLC now owns 15,004 shares of the medical technology company’s stock worth $2,963,000 after purchasing an additional 423 shares during the period. 73.48% of the stock is owned by institutional investors and hedge funds.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Story: Intrinsic Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.